ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 609,15
-0,69%
Dow Jones
39 127,80
0,04%
DAX
18 155,24
-0,04%
Brent Oil
84,155
-0,37%
Bitcoin
60 974,52
0,27%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Galectin Therapeutics Inc (GALT)

  7. Galectin Therapeutics Inc (GALT) Actualités

GALT

Galectin Therapeutics (GALT)

Galectin Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:GALT
DateHeureSourceTitreSymboleSociété
20/06/202419h55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GALTGalectin Therapeutics Inc
15/05/202413h55Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GALTGalectin Therapeutics Inc
15/05/202413h50Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:GALTGalectin Therapeutics Inc
01/12/202322h50Edgar (US Regulatory)Form 5 - Annual statement of changes in beneficial ownership of securitiesNASDAQ:GALTGalectin Therapeutics Inc
01/12/202322h38Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:GALTGalectin Therapeutics Inc
13/11/202315h21Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:GALTGalectin Therapeutics Inc
13/11/202314h45GlobeNewswire Inc.UPDATE – Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business UpdateNASDAQ:GALTGalectin Therapeutics Inc
13/11/202314h00GlobeNewswire Inc.Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business UpdateNASDAQ:GALTGalectin Therapeutics Inc
03/11/202313h00GlobeNewswire Inc.Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2023, Hosted by the AASLDNASDAQ:GALTGalectin Therapeutics Inc
23/10/202314h00GlobeNewswire Inc.Galectin Therapeutics to Participate in the H.C. Wainwright 7th Annual NASH Investor Conference on October 24, 2023NASDAQ:GALTGalectin Therapeutics Inc
16/10/202318h36Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:GALTGalectin Therapeutics Inc
12/10/202314h00GlobeNewswire Inc.Galectin Therapeutics Announces Nomination of Dr. Benjamin S. Carson, Sr. to Board of DirectorsNASDAQ:GALTGalectin Therapeutics Inc
06/10/202314h08Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:GALTGalectin Therapeutics Inc
06/10/202314h05Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:GALTGalectin Therapeutics Inc
06/10/202314h03Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:GALTGalectin Therapeutics Inc
03/10/202314h00GlobeNewswire Inc.Galectin Therapeutics Reports the Positive Outcome of the Fourth Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Portal Hypertension Caused by Non-Alcoholic SteatoHepatitis LiverNASDAQ:GALTGalectin Therapeutics Inc
26/09/202314h00GlobeNewswire Inc.Galectin Therapeutics to Present Update on its Belapectin Liver Cirrhosis Program at the 20th Edition of Discovery on Target meeting, in Boston, September 25-28, 2023NASDAQ:GALTGalectin Therapeutics Inc
11/09/202322h38Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:GALTGalectin Therapeutics Inc
11/09/202314h00GlobeNewswire Inc.Galectin Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023NASDAQ:GALTGalectin Therapeutics Inc
07/09/202318h00GlobeNewswire Inc.Galectin Therapeutics to Present Data on Liver Cirrhosis at the 9th Edition of the Paris NASH meeting, at Institut Pasteur, September 7th & 8th 2023NASDAQ:GALTGalectin Therapeutics Inc
14/08/202314h00GlobeNewswire Inc.Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2023 and Provides Business UpdateNASDAQ:GALTGalectin Therapeutics Inc
16/06/202313h51Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:GALTGalectin Therapeutics Inc
15/05/202314h00GlobeNewswire Inc.Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2023 and Provides Business UpdateNASDAQ:GALTGalectin Therapeutics Inc
15/05/202313h56Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:GALTGalectin Therapeutics Inc
27/04/202314h00GlobeNewswire Inc.Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Investment Conference May 2, 2023NASDAQ:GALTGalectin Therapeutics Inc
25/04/202312h06Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:GALTGalectin Therapeutics Inc
18/04/202314h00GlobeNewswire Inc.Galectin Therapeutics’ Statement Following the Recent 2023 Emerging Topic Conference on NASH Cirrhosis, Sponsored by the American Association for the Study of Liver DiseasesNASDAQ:GALTGalectin Therapeutics Inc
14/04/202323h27Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:GALTGalectin Therapeutics Inc
30/03/202322h01Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:GALTGalectin Therapeutics Inc
30/03/202314h00GlobeNewswire Inc.Galectin Therapeutics Reports 2022 Financial Results and Provides Business UpdateNASDAQ:GALTGalectin Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:GALT

Dernières Valeurs Consultées

EU
RNO
Renault
COIN
ETHUSD
Ethereum
EU
PX4
SBF 120
EU
HO
Thales
EU
PX1
CAC 40
EU
GLE
Societe Generale
USI
USTECH100
US Tech 100
EU
ACA
Credit Agricole
EU
CS
Axa
EU
DG
Vinci
NASDAQ
GOOGL
Alphabet
FTSE
UKX
FTSE 100
SPI
SP500
S&P 500
NYSE
MCD
McDonalds
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés